Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

ClinicalTrials.gov ID: NCT03432260

Public ClinicalTrials.gov record NCT03432260. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis

Study identification

NCT ID
NCT03432260
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Durect
Industry
Enrollment
19 participants

Conditions and interventions

Interventions

  • DUR-928 30 mg Drug
  • DUR-928 90 mg Drug
  • DUR-928 150 mg Drug

Drug

Eligibility (public fields only)

Age range
21 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 17, 2018
Primary completion
Sep 8, 2019
Completion
Sep 8, 2019
Last update posted
Sep 23, 2024

2018 – 2019

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
DURECT Study Site 0001 San Diego California 92118
DURECT Study Site 007 Miami Florida 33136
DURECT Study Site 0004 Atlanta Georgia 30309
DURECT Study Site 0002 Chicago Illinois 60611
DURECT Study Site 008 Indianapolis Indiana 46202
DURECT Study Site 0005 Louisville Kentucky 40202
DURECT Study Site 006 San Antonio Texas 78215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03432260, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 23, 2024 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03432260 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →